Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. - Wikidata - awgldk - TriplyDB

Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention.

Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention.

http://www.wikidata.org/entity/Q34366988

about

Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy Bile Acid diarrhea: prevalence, pathogenesis, and therapy Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study Review article: bile acid diarrhoea - pathogenesis, diagnosis and management Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study Systematic review: the management of chronic diarrhoea due to bile acid malabsorption.Advances in understanding of bile acid diarrhea.Commentary: fibroblast growth factor 19 in patients with bile acid diarrhoea The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.Validating biomarkers of treatable mechanisms in irritable bowel syndrome Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome Regulation of bile acid homeostasis by the intestinal Diet1-FGF15/19 axis.Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy.The role of bile acids in functional GI disorders.Bile acid malabsorption in inflammatory bowel disease.Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis.Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea.Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples.Bile acid disease: the emerging epidemic.The Farnesoid X Receptor: Good for BAD.Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS.Mechanisms of triglyceride metabolism in patients with bile acid diarrhea.Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis.Diet1, bile acid diarrhea, and FGF15/19: mouse model and human genetic variants.Editorial: diagnosing bile acid diarrhoea with blood tests.Editorial: developing a stimulation test to identify FGF19 deficiency in bile acid diarrhoea.Chenodeoxycholic acid stimulated fibroblast growth factor 19 response - a potential biochemical test for bile acid diarrhoea.A positive SeHCAT test results in fewer subsequent investigations in patients with chronic diarrhoea.Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.Dissecting Molecular Mechanisms in Bile Acid Diarrhea.Diarrhea in Crohn’s disease: investigating the role of the ileal hormone fibroblast growth factor 19.Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea.Challenging current views on bile acid diarrhoea and malabsorption.Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.

P2860

Q26751193-EB2804E6-127C-4154-9E35-3D4910B18F68 Q26781556-04A7D94B-8C4B-4358-AF21-8F623D94079A Q28086845-22C54816-1048-4A25-9F2E-CA538E338A86 Q28242569-DE027CDD-8395-434D-916D-5522E433C228 Q28273649-B1987E94-B4A6-496E-B14D-0CD4316F7057 Q33805921-7B453E0D-AA80-4793-B5DA-1AC7CDF413D4 Q34408666-05B6963E-9B85-4959-8F01-637DE64CA208 Q34412381-F787A363-608E-400A-80F1-888C9538C8B2 Q34426461-224412D0-7FFB-4775-A338-E88CBA30E521 Q34444158-A574A72F-1481-4569-BC0E-51453ADCFE9B Q34577283-83931563-274B-4CE3-BFED-F305787B8906 Q35825711-BD81E23D-A1C7-4428-BF65-BCF2E58D14A5 Q35836340-9817E494-693B-465B-92F1-A29C0A0288D3 Q38198859-9E1D2FF8-66A4-4E4D-8AE7-990368D849A9 Q38217671-9B19A42D-36AE-4402-9DC3-0C07399052A4 Q38253467-0DBE323A-9633-4933-96AA-06961A9B5662 Q38445280-54FE0408-79DB-4480-A629-9E422A33C048 Q38582664-7E27E506-9561-497A-92B7-D7C807D1D8E6 Q38687017-07DF3775-CD54-42FD-B884-0F62D2A2CEDF Q38699388-75D7F2F8-B37C-46C9-B735-E7FFEB536EAF Q39124316-C9264A6E-A491-4345-BD48-4EA685E90DEB Q39125255-BF5E6D46-A3B6-407E-ADCF-63563AB2DAC2 Q39208620-241E1327-E83D-4549-9613-F78B422E328C Q39444895-E4FB8677-99B5-44EF-AEFB-969EA36289AB Q43270593-3512716E-6BD8-40F8-9C2E-3F2E68BE6B41 Q47237068-53BFB314-4878-4417-9FA2-7D9AD5B829B4 Q48112817-A7E57321-2AB4-4F68-89E5-244F06CF54FF Q48315900-702946DD-1C63-4BD5-86F4-CE3159A8C16C Q48319424-67B92BAD-A088-4D64-A44C-A571A88D6325 Q50079125-0512240A-256A-4964-B45D-8222068C4C06 Q50535134-6B7B4D2D-554D-4F8D-8DDB-B1A02C78C859 Q51286764-5CBB47F1-0A0B-4DDD-AB20-C526E6F8040F Q51310817-03801723-D3BD-4591-9B35-BFEAC9CC5EDB Q51318198-60367C4C-849F-4951-BC5D-2C7EAF848226 Q52626566-4D0C0211-3EA1-47FB-B757-C2FFE4757985 Q55345479-A634E674-4459-405F-AC8E-5AB877DE2BB3

P2860

Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention.

http://www.wikidata.org/entity/Q34366988

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.

@ast

Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.

@en

Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.

@nl

type

label

Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.

@ast

Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.

@en

Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.

@nl

prefLabel

Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.

@ast

Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.

@en

Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.

@nl

P1433

Q34366988-8BABC2AF-FD75-45EF-B17C-D4535257DFA1

P1476

Q34366988-9CAE908C-C1BC-4FDD-922D-4104A5DDC7ED

P2093

Q34366988-081AEF19-533E-45A0-8A74-EED8DF29DC5C

Q34366988-126B1FA6-E879-4C43-A829-CEEE7B9A3408

Q34366988-20058C36-F5DB-4F96-AAAD-A95286940B69

Q34366988-2413A8A4-7751-4D58-B0A3-AC542C59DFEF

Q34366988-6645513B-7AD5-4639-8B8B-62358CDCE5F9

Q34366988-814E1246-9D29-4547-A3B1-35890FB6EAE7

Q34366988-BBEF1F7C-475A-498B-8B07-A4686C3EFA7D

Q34366988-ECB801F3-ADFE-400C-B135-D9656B5F1FA0

Q34366988-F4C74BF8-9466-4A39-8B48-A8CABEAFF3BE

P2860

Q34366988-09E8499E-7080-4C96-94F8-9C7A07AE39A8

Q34366988-0BC179CE-45D4-40D3-937A-8DF370CB548D

Q34366988-16B48FC6-D7CB-4C9F-8040-5BC434238433

Q34366988-1BC5AE11-8886-4F56-8860-FEE2988EFDA0

Q34366988-1C063A66-9B2E-403A-8A06-A6B470E7409C

Q34366988-29014367-257C-4F86-8BD0-221E517AA94E

Q34366988-35EABDA0-6775-436B-B5E1-52B482AC128E

Q34366988-37B17C01-824D-4988-8CA9-356CBFE0AFA4

Q34366988-416044C4-C75E-47B0-9DF3-47C4428DCEB8

Q34366988-42BA0F91-C03D-4884-886F-F0E86B50C75A

P304

Q34366988-A714C235-DB07-420B-81D0-1AE5EBA57801

P31

Q34366988-A7B1672D-6BA7-4F20-8002-CE60B84F2534

P356

Q34366988-87A8DC66-F065-4CC4-862F-26B0B3A0C585

P407

Q34366988-DB642B10-A6EF-47CF-9A6D-0DE035FB213F

P433

Q34366988-0CDA09BC-FECA-46B1-9137-E6495050174B

P478

Q34366988-87FF58F3-815D-42E3-A159-B2FF95643FE7

P577

Q34366988-0B0FC219-A1E7-49CE-88DB-C8AFABBAB4F0

P698

Q34366988-5DA63E1D-9EF0-4CB8-8D63-C461B20D7830

P921

Q34366988-ACCF88FE-7F8B-4EDC-AFE0-5C5E3E8B6370

Q34366988-D241E006-B8C4-4176-8A09-AE2AC5244E8B

P356

P1433

Alimentary Pharmacology & Therapeutics

P1476

Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.

@en

P2093

I M Johnston

http://www.w3.org/2001/XMLSchema#string

J D Nolan

http://www.w3.org/2001/XMLSchema#string

J R F Walters

http://www.w3.org/2001/XMLSchema#string

K D Bardhan

http://www.w3.org/2001/XMLSchema#string

M Srinivas

http://www.w3.org/2001/XMLSchema#string

P Basumani

http://www.w3.org/2001/XMLSchema#string

S S Pattni

http://www.w3.org/2001/XMLSchema#string

T Dew

http://www.w3.org/2001/XMLSchema#string

W G Brydon

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release

FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis

Managing bile acid diarrhoea

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis

Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function

Recent advances in the understanding of bile acid malabsorption

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder.

Cholestyramine treatment of diarrhea associated with ileal resection.

Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys.

P304

967-976

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/APT.12466

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23981126

http://www.w3.org/2001/XMLSchema#string

P921

Afọ ọsịsa